Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Axios Visuals
Antibody treatments are showing promise as an important tool against the coronavirus, but there aren't going to be a lot of them at first and they could also come with hefty price tags.
Driving the news: Regeneron announced on Wednesday that its antibody cocktail reduced infected patients’ need to visit the doctor or go to the hospital by 57% — but there are only 50,000 doses available right now, Stat reports.
- The treatment is given early on in the course of the disease, meaning that it can't be rationed for only the sickest patients.
- The company is ramping up production and expects to be able to produce 300,000 doses in the coming months.
- Eli Lilly has said that it could ship 100,000 doses of its single antibody if it's cleared by regulators, and could produce up to a million doses by the end of the year.
Between the lines: Lilly has agreed to provide 300,000 doses of its antibody to the federal government, which plans to distribute them at no cost.
- However, the therapy is given by intravenous infusion, which can cost well over $1,000, NPR reports. Insured patients could end up on the hook for hundreds of dollars in out-of-pocket costs.
- That means that infected patients — of which only a small percentage require hospitalization — will have to decide whether it's worth getting the treatment, and possibly an expensive bill, in order to reduce the risk of future hospitalization from the virus.